AJANTA PHARMA has announced its results for the quarter ended September 2019. Here is a detailed performance review of the same:
No. of Mths Qtr. Ending | 3 Sep-18* | 3 Jun-19* | 3 Sep-19* | QoQ Change | YoY Change | |
---|---|---|---|---|---|---|
Net Sales | Rs m | 5,441 | 6,119 | 6,428 | 5.0% | 18.1% |
Other income | Rs m | 152 | 76 | 132 | 73.0% | -13.3% |
Turnover | Rs m | 5,594 | 6,196 | 6,560 | 5.9% | 17.3% |
Expenses | Rs m | 3,779 | 4,436 | 4,651 | 4.9% | 23.1% |
Gross profit | Rs m | 1,662 | 1,684 | 1,766 | 4.9% | 6.2% |
Depreciation | Rs m | 175 | 228 | 233 | 2.3% | 33.2% |
Interest | Rs m | 1 | 18 | 49 | 175.4% | 3692.3% |
Profit before tax | Rs m | 1,638 | 1,515 | 1,616 | 6.7% | -1.4% |
Tax | Rs m | 385 | 368 | 452 | 22.8% | 17.6% |
Profit after tax | Rs m | 1,254 | 1,146 | 1,164 | 1.5% | -7.2% |
Gross profit margin | % | 30.5 | 27.5 | 27.5 | ||
Effective tax rate | % | 23.5 | 24.3 | 28.0 | ||
Net profit margin | % | 22.4 | 18.5 | 17.7 |
To see how AJANTA PHARMA has performed over the last eight quarters,please visit here.
Listen In: Our Investor Hour Podcast Connects You with the World's Most Successful Investors
Over the last one year,AJANTA PHARMA share price has moved down from Rs 1,058.0 to Rs 996.0, registering a Loss of Rs 62.0 or around 5.9%.
Meanwhile, the S&P BSE HEALTHCARE Index is trading at Rs 13,228.6 (down 0.7%). Over the last one year it has moved down from 14,540.6 to 13,228.6, a gain of 1,312 points (down 9.0%).
Overall, the S&P BSE SENSEX is up 15.1% over the year.
At the current price of Rs 996.0, the price to earnings (P/E) ratio of AJANTA PHARMA stands at 22.6 times its trailing twelve months earnings, while its price to book value (P/BV) ratio stands at 3.9 times.
| |
For the quarter ended June 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 8.4% YoY). Sales on the other hand came in at Rs 6 bn (up 19.8% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.
Here's an analysis of the annual report of AJANTA PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AJANTA PHARMA. Also includes updates on the valuation of AJANTA PHARMA.
For the quarter ended March 2019, AJANTA PHARMA has posted a net profit of Rs 889 m (down 5.9% YoY). Sales on the other hand came in at Rs 5 bn (down 2.9% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.
Should you subscribe to the IPO of Aster DM Healthcare Ltd?
More Views on NewsWhat we can learn from one of the greatest traders to have ever lived.
What to do after every trade.
Should you invest in growth stocks or value stocks to make strong returns in this market?
This corner of the market could provide more returns than blue chips in 2020.
2019 will be remembered as the year of great money-making IPOs...
More
| |
Equitymaster requests your view! Post a comment on "AJANTA PHARMA Announces Quarterly Results (2QFY20); Net Profit Down 7.2%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!